Back to results
US 2017/0304344 A1Published application
Compositions and methods for treating viral infections
AssigneeSpring Bank Pharmaceuticals, Inc.
InventorsRadhakrishnan P. Iyer, Seetharamaiyer Padmanabhan
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions methods for treating susceptible viral infections, especially hepatitis C viral (HCV) infections as well as co infections of HCV with other viruses such as HBV and/or HIV. In one embodiment, the present invention provides compositions having the formula (I) and their use in treating viral infections: or a pharmaceutically acceptable salt, ester, stereoisomer, tautomers, solvate, prodrug, or combination thereof.
Claims10
A method of treating HCV infection comprising administering to a patient in need of such treatment an effect amount of a compound of formula I:
- or a pharmaceutically acceptable salt, ester, stereoisomer, tautomers, solvate, prodrug, or combination thereof, wherein:
- N1 and N2 are independently selected from naturally occurring nucleosides or modified nucleosides;
- W, X, Y and Z are each independently selected from O, S and NR1 wherein R1 is independently selected from hydrogen, substituted or unsubstituted aliphatic group and substituted or unsubstituted aromatic group;
- R2, R3, R4 and R5 are each independently selected from hydrogen, substituted or unsubstituted aliphatic group and substituted or unsubstituted aromatic group;
- n is 0, 1, 2, 3, 4 or 5;
- A is absent, or substituted or unsubstituted aromatic group;
- J is absent, CR6R7, O, S or NR1 wherein R6 and R7 are each independently selected from hydrogen, substituted or unsubstituted aliphatic and substituted or unsubstituted aromatic group;
- M is absent, CR8R9, O, S or NR1 wherein R8 and R9 are each independently selected from hydrogen, substituted or unsubstituted aliphatic group and substituted or unsubstituted aromatic group;
- V is substituted or unsubstituted aliphatic group or substituted or unsubstituted aromatic group;
- Q is absent, or a modified or unmodified nucleotide;
- and
- m is 1, 2, or 3.
9 more elements
A method of treating HCV comprising administering a compound having the formula III:
- or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, prodrug, or combination thereof, wherein:
- M′ and M″ are each independently selected from CH2, NH, NR″, O, and S;
- wherein R″ is substituted or unsubstituted aliphatic group or substituted or unsubstituted aromatic group;
- X′ is O, NH, NR″, or S;
- wherein R″ is as previously defined;
- Y′ is OR12, NHR12, and SR12;
- where each R12 is independently selected from H, substituted or unsubstituted aliphatic group or substituted or unsubstituted aromatic group;
- Z′ and Z″ are each independently O, NR13, and S;
- where R13 is H, substituted or unsubstituted aliphatic group or substituted or unsubstituted aromatic group;
- R and R′ are each independently H, OH, O-alkyl, O-aryl, O-heteroaryl, O-aralkyl, O-alkyl heteroaryl, —NH2, —NHR14, —NR15NR16, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heterocyclic, wherein R14, R15 and R16 are each independently selected from H, substituted or unsubstituted aliphatic group or substituted or unsubstituted aromatic group;
- B1 and B2 are each independently selected from absent, H, naturally occurring nucleobases and modified bases;
- and
- Q′ is absent or
- wherein X′ and Y′ are as previously defined and A is OH, O-alkyl, O-aryl, O-heteroaryl, O-aralkyl, or O-alkyl heteroaryl.
11 more elements
A method of treating HCV comprising administering a compound having the formula IV:
- M′ is selected from CH2, NH, NR″, O, and S;
- wherein R″ is substituted or unsubstituted aliphatic group or substituted or unsubstituted aromatic group;
- X is O, NH, NR″, or S where R″ is previously defined;
- Z′ is H, OH, OR″, OR17, COOH, COOR″, NH2, NHR″, NHR17 where R″ is previously defined and R17 is aroyl (CO-Ph), sulfonyl (SO2—R), ureidyl (CO—NH—R), thioureidyl (CS—NH—R) wherein R is selected from hydrogen, substituted or unsubstituted aliphatic group and substituted or unsubstituted aromatic group however, when M′ is O, Z′ is not OH;
- R′ is H, OH, O-alkyl, O-aryl, O-heteroaryl, O-aralkyl, O-alkyl heteroaryl, O-aroyl, —NH2, —NHR1, —NR1NR2 alkyl, substituted alkyl, cycloalkyl, aryl, substituted aryl, aralkyl, or heterocylic wherein R1 and R2 are each independently selected from hydrogen, substituted or unsubstituted aliphatic group and substituted or unsubstituted aromatic group, however when M′ is O, R′ is not OH;
- B1 is H, a naturally occurring nucleobase or a modified base.
3 more elements
Dependencies are inferred from the claim text.